Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas

Clinical trial NCT07778602 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07778602
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status: NOT_YET_RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

MGMT-unmethylated Glioblastoma (GBM)IDH Wildtype Glioblastoma

Start date: 2026-11-10
Primary completion: 2028-11-10
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.